Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 214 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Prednisone or prednisolone Clear all

Conditions: Generalized Myasthenia Gravis, gMG
Interventions: Oral Corticosteroid Tapering Schedule, Ravulizumab, Prednisone/Prednisolone; Procedure · Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Chicago, Illinois • Schaumburg, Illinois • Neptune City, New Jersey + 2 more

Conditions: Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
Interventions: ASP5541, Prednisone, Prednisolone, abiraterone acetate, Adrenocorticotropic hormone; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 12
States / cities: Huntsville, Alabama • San Diego, California • Tampa, Florida + 9 more

Conditions: Prostate Cancer
Interventions: Cabazitaxel (XRP6258), Prednisone (or Prednisolone); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 21
States / cities: Muscle Shoals, Alabama • Hot Springs, Arkansas • Anaheim, California + 18 more

Conditions: Lymphoma, Follicular
Interventions: inotuzumab ozogamicin, rituximab, cyclophosphamide, vincristine, prednisone/prednisolone, mitoxantrone, fludarabine, dexamethasone; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 17
States / cities: Mission Hills, California • Evansville, Indiana • Baltimore, Maryland + 13 more

Conditions: Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Interventions: Biospecimen Collection, Bleomycin Sulfate, Brentuximab Vedotin, Computed Tomography, Cyclophosphamide, Dacarbazine, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Fludeoxyglucose F-18, Involved-site Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Prednisolone, Prednisone, Procarbazine Hydrochloride, Questionnaire Administration, Vinblastine Sulfate, Vincristine Sulfate; Procedure · Biological · Drug + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 5 Years to 60 Years
Enrollment: 1,875 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 404
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 298 more

Conditions: Cranial Nerve Disorder, Head and Neck Carcinoma, Oropharyngeal Carcinoma
Interventions: Methylprednisolone, Prednisone, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Castration Resistant Prostate Cancer
Interventions: Rucaparib, Abiraterone acetate or Enzalutamide or Docetaxel; Drug
Lead sponsor: pharmaand GmbH; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 61
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more

Conditions: Ulcerative Colitis Acute
Interventions: Oral Upadacitinib, Intravenous Methylprednisolone, Oral Upadacitinib Placebo, Oral prednisolone Taper, Oral Prednisone - Hospital Dose Steroids; Drug
Lead sponsor: Berinstein, Jeffrey; Other
Eligibility: 18 Years to 75 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Orthostatic Hypotension, Hemodynamic Instability, Fever, Hypothermia
Interventions: Hydrocortisone High Dose, Hydrocortisone Low Dose; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Covid19
Interventions: Aviptadil, Aviptadil Placebo, Corticosteroid; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 40
States / cities: Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more

Conditions: Status Asthmaticus
Interventions: Ipratropium, 0.9% Sodium Chloride, Albuterol, corticosteroids; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 2 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Gout
Interventions: Pegloticase, methotrexate, placebo, folic acid, gout flare prophylaxis regimen, fexofenadine, acetaminophen, methylprednisolone; Biological · Drug · Dietary Supplement
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 60
States / cities: Birmingham, Alabama • Anchorage, Alaska • Flagstaff, Arizona + 54 more

Conditions: Lymphoma, Non-Hodgkin
Interventions: Copanlisib (BAY80-6946), Placebo, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Bendamustine, Prednisone; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 10
States / cities: Chandler, Arizona • West Covina, California • Denver, Colorado + 6 more

Conditions: Asses Immunosuppression Modulation on Renal Recovery Post LT
Interventions: Basiliximab 20 MG; Drug
Lead sponsor: Fady M Kaldas, M.D., F.A.C.S.; Other
Eligibility: 18 Years to 78 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypereosinophilic Syndrome
Interventions: Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or prednisone), Placebo matching OCS capsules; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: San Diego, California • New Haven, Connecticut • Rochester, Minnesota + 4 more

Conditions: Diffuse B-Cell Lymphoma
Interventions: Avadomide (CC-122), Rituximab, Cyclophosphamide 750mg/m2 by IV infusion, Vincristine, Prednisone; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Tampa, Florida • St Louis, Missouri

Conditions: Prostate Cancer
Interventions: AT13387, abiraterone acetate, Prednisone; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 20
States / cities: Los Angeles, California • Stanford, California • Fort Lauderdale, Florida + 16 more

Conditions: Graft-versus-host Disease (GVHD)
Interventions: Ruxolitinib, Prednisone or methylprednisolone; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 38
States / cities: Tucson, Arizona • Duarte, California • La Jolla, California + 29 more

Conditions: Systemic Sclerosis-Associated PAH
Interventions: Rituximab, Placebo, CMRI, prednisone, methylprednisolone, diphenhydramine, acetaminophen; Biological · Other · Diagnostic Test + 1 more
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 17
States / cities: Stanford, California • Aurora, Colorado • Iowa City, Iowa + 13 more

Conditions: Allografts, Rejection; Transplant, Kidney, Transplant Rejection, Kidney Transplantation
Interventions: Belatacept, VIB4920, Thymoglobulin, Methylprednisolone; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: Los Angeles, California • San Francisco, California • Durham, North Carolina + 1 more

Conditions: Diffuse Large B-cell Lymphoma (DLBCL)
Interventions: Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/Prednisolone; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 904 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 23
States / cities: Scottsdale, Arizona • Los Angeles, California • Orange, California + 19 more

Conditions: Healthy Volunteers
Interventions: Deflazacort and rifampin, Deflazacort and Clarithromycin; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Prostate Cancer
Interventions: Abiraterone, Apitolisib, Ipatasertib, Placebo, Prednisone, Prednisolone; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 12
States / cities: Scottsdale, Arizona • San Francisco, California • Fort Myers, Florida + 9 more

Conditions: Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
Interventions: Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Echocardiography Test, FDG-Positron Emission Tomography, Leucovorin, Levoleucovorin, Lumbar Puncture, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Methylprednisolone, Multigated Acquisition Scan, Prednisolone, Prednisone, Therapeutic Hydrocortisone, Thioguanine, Venetoclax, Vincristine; Drug · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 365 Days
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 116
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 100 more

Search by objective public record fields.

A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors

A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis

Trial Comparing Low Dose and High Dose Steroids in Patients Undergoing Colorectal Surgery

Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

Phase I, Placebo-Controlled, Blinded Pilot Study of Ipratropium in Children Admitted to the ICU With Status Asthmaticus

Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)

Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

Evaluate Effects of Multiple Doses of Rifampin and Clarithromycin on the Single Dose Pharmacokinetics of Deflazacort

Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia